The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RPX7009(beta-lactamase inhibitor) is being studied in combination with carbapenem (RPX2014)to
treat bacterial infections, including those due to multi-drug resistant bacteria.
Phase:
Phase 1
Details
Lead Sponsor:
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)